Novartis Vaccines & Diagnostics, Gmbh

Pharmabcine Inc.

Sang Hoon Lee

Hyuk Jin Lee

Li Long

Seon Young Lee

Sung Woo Kim

Young Ae Lee

Do Yun Kim

Weon Sup Lee

Mohammad Luqman

Sang Soon Byun

Asha Yabannavar

Jae Bong Yoon

Sang Ryeol Shim

In Sook Park

Jin San Yoo

Seon Hwan Oh

Jong Geun Jeong

Nam Ye Kim

Joong Kyu Kim

Isabel Zaror

Eun Jin Lee

Jin Sang Yoo

Mi Ju Park

Yeun Ju Kim

Kyung Hee Nahm

Ju Ryung Nam

Jin Hee Choi

Jin Sook Lee

Bo Young Jeong

Deborah Hurst

Bao-lu Chen

Carla C Heise

Xiaofeng Lu

Hyuk Joon Lee

Bao-Lu Chen

Mohammed Luqman

The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.

Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same

Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.

Antagonist anti-CD40 monoclonal antibodies and methods for their use

Antagonist anti-CD40 antibodies

Methods of using compounds having Structure I or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein. 

Modulating and measuring cellular adhesion

Growing community of inventors

Palo Alto, CA, United States of America

Sang Hoon Lee